Reduces Nrf2 expression in non-small-cell lung cancer cells, leading to GSH depletion [160]Sensitizes cells to oxaliplatin, bleomycin, doxorubicin [160,161]. Re-sensitizes oxaliplatin-resistant colorectal cancer cells [68]Inhibits Nrf2 in xenografts [162]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.